Rituximab Treatment in Hepatitis C Infection: An In Vitro Model to Study the Impact of B Cell Depletion on Virus Infectivity

Hepatitis C virus (HCV) infected patients with vasculitis are often treated with the B-cell-depleting anti-CD20 antibody rituximab. Treatment reduces the cryoglobulins that cause vasculitis, yet it also leads to a transient increase in liver enzymes and HCV genomic RNA in the periphery. The mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Stamataki, Zania, Tilakaratne, Samantha, Adams, David H., McKeating, Jane A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184166/
https://www.ncbi.nlm.nih.gov/pubmed/21991396
http://dx.doi.org/10.1371/journal.pone.0025789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184166/
https://www.ncbi.nlm.nih.gov/pubmed/21991396
http://dx.doi.org/10.1371/journal.pone.0025789

Ejemplares similares